Skip to main content
. Author manuscript; available in PMC: 2021 Nov 8.
Published in final edited form as: J Subst Abuse Treat. 2018 Jul 31;94:81–90. doi: 10.1016/j.jsat.2018.07.014

Table A-2.

Cost-effectiveness results using GEE modeling.

Treatment
Arm
N Average total cost of treatment per participant
episode (2015$)
Past 30 days abstinent from heroin
in 30 days prior to 12-month
follow-up (self-reported)
Percentage of participants with a
negative opioid urine screen at 12-
month follow-up
Average cost
(SE)
Mean
effectiveness ±
(SE)
Incremental CE
ratio
(ΔC/ΔE)
Mean
effectiveness ±
(SE)
Incremental CE
ratio
(ΔC/ΔE)
TAU 149 $2292 20.0 39%
(108.26)
PCM 146 $2396 20.5 $196 40% $8317
(102.64)

Note: Standard errors (SE) are presented in parenthesis.